Meeting
Subcommittee on Health Oversight Hearing
Body
House Committee On Veterans' Affairs
Date
November 19, 2026
Jurisdiction
Federal
The House Committee on Veterans’ Affairs Subcommittee on Health held an oversight hearing on emerging psychedelic-assisted therapies for veterans on November 19, 2026. Members and witnesses discussed potential treatments for PTSD, depression, and substance use disorders, emphasizing that VA should prioritize safety, evidence, and appropriate regulatory approval. VA described its research portfolio, a psilocybin trial launched in August 2026, agreements with HHS and FDA to coordinate research and preparation, and plans to prepare 10 facilities for possible early implementation, including clinician training, care protocols, and facility standards. FDA approval, DEA rescheduling, and relevant state requirements were identified as steps that could affect when treatment becomes available.
Discussion focused on staffing, access for rural veterans, community-care providers, informed consent, safety monitoring, and continued research. Members raised the need for dedicated funding and witnesses recommended supporting VA readiness through its medical-care budget, staffing, clinical infrastructure, and evaluation of qualified community partners. A VA representative agreed to provide the committee within 30 days with a staffing plan and the list of the 10 sites. No contract awards, vendor selections, or purchasing votes were identified; the hearing included no spending or procurement approval.
Source
House Committee On Veterans' Affairs